


What is TIM ?

A major challenge using healthy donor cells when developing CAR T therapies is a potentially life-threatening condition called graft-versus-host disease (GvHD). GvHD occurs when allogeneic CAR T cells recognize the patient's healthy tissues as foreign and attack them. This can be avoided by blunting the activity of the T cell receptor present on every CAR T cell.



TIM Incorporating TCR Complex

- The T cell receptor is a multi-protein complex that uses the CD3ζ chain as its main signaling partner.
- Our T cell receptor Inhibitor Molecule (TIM) is a small peptide that interferes with the ability of the TCR to signal.
- TIM works with our NKG2D CAR T to inhibit CD3ζ activity, prevent GvHD and enable anti-tumor activity through the NKG2D CAR T.

What are the advantages of using a TIM approach?

- All the elements required to generate the allogeneic CAR T are included within a single vector – the 'All-in-One vector' design.
- No need for multiple manipulations or complicated manufacturing strategies as required for many alternative gene editing methods.
- Allows for a short manufacturing process – this is important as extensive culture times impact the clinical efficacy of T cell therapies.